Dawn Maier
About Dawn Maier
Dawn Maier serves as the Vice President of Emerging Technologies in Cell and Gene Therapies at ElevateBio, where she has worked since 2021. With over 20 years of experience in the field, she has held various leadership roles and contributed to the development of several commercial products.
Current Role at ElevateBio
Dawn Maier serves as the Vice President of Emerging Technologies focusing on Cell and Gene Therapies at ElevateBio. She has held this position since 2021, contributing to advancements in the field from the United States. Her role involves overseeing the development of innovative technologies that enhance the capabilities of cell and gene therapies.
Previous Experience at ElevateBio
Prior to her current role, Dawn Maier worked at ElevateBio as the Senior Director of Process Development & Manufacturing from 2019 to 2021. In this capacity, she was responsible for leading process development initiatives. She also held the position of Vice President of Process Development for a brief period in 2021, focusing on operational strategies in Waltham, Massachusetts.
Experience at bluebird bio
Dawn Maier has extensive experience at bluebird bio, where she held multiple roles from 2013 to 2017. She started as a Scientist I and progressed to Senior Manager of Cell & Gene Therapy, and then to Associate Director of Cellular Process Development & Manufacturing. Her work involved significant contributions to the development of cellular therapies.
Education and Expertise
Dawn Maier holds a Bachelor’s degree in Biology from Catawba College and a Master of Science in Biology from Western Carolina University. She also studied Biology at Elizabethtown College. With over 20 years of experience in the cell and gene therapy field, she has developed expertise in managing contract manufacturing organizations (CMOs) and driving process and analytical development for therapies targeting cancer, HIV, and rare genetic diseases.
Contributions to Commercial Products
Dawn Maier has played a significant role in the development of several commercial products, including Kymriah, Abecma, Zynteglo, and Skysona. Her work has involved pre-clinical development and CMC activities essential for various phases of clinical trials, as well as optimizing lentiviral vectors for functional and safety features.